December 1, 2014 marked World AIDS Day, with roughly 40 million deaths worldwide over the past three decades attributed to this virulent disease. While there is no known cure for AIDS the advent of multiple drug regimens has made the treatment of the HIV virus which causes AIDS manageable for many patients globally. Unfortunately there[…]
Winning the Fight Against AIDS One Drug at a Time
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API Tags: antiretroviral therapyHIV virus Dec 02, 2014
Lamivudine Is Still a Formidable Treatment for HIV and HBV
Anti-Retroviral / Anti-HIV, Antiviral, Patent Expiration 2016 Tags: antiretroviral therapychronic hepatitis BHIV virus Nov 12, 2012
Lamivudine is also known as Epvir. Marketed by GlaxoSmithKline, the patent for Epvir is due to expire on May 18, 2016. Lamivudine is an antiviral medication that prevents human immunodeficiency virus (HIV) or hepatitis B (HBV) virus cells from multiplying in the body. This medication will treat HIV and HBV, but it is not a[…]
Tesamorelin and Breaking News from the United Nations AIDS Program
Anti-Retroviral / Anti-HIV, Antiviral Tags: antiretroviral therapyHIV Jul 19, 2012
The United Nations AIDS program announced on Wednesday, July 18th, 2012 that fewer people infected with HIV globally were dying, particularly in sub-Saharan Africa. The reason for this encouraging news is the greater accessibility for patients with AIDS worldwide to crucial antiretroviral drugs. The U.N. is actively working alongside pharmaceutical companies, in an effort to[…]